What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Cancer
- Biochemistry
Her primary areas of study are Radionuclide therapy, Somatostatin, Internal medicine, Endocrinology and Octreotide.
Her biological study spans a wide range of topics, including Receptor and Cancer research.
Her Somatostatin research includes themes of Pharmacology, Peptide and Pathology.
Her Internal medicine study frequently involves adjacent topics like Oncology.
Within one scientific family, Marion de Jong focuses on topics pertaining to Pharmacokinetics under Endocrinology, and may sometimes address concerns connected to Arginine.
Her studies in Octreotide integrate themes in fields like Neuroendocrine tumors, Radiation therapy, Biodistribution and DOTA.
Her most cited work include:
- [177Lu-DOTA0, Tyr3]octreotate : comparison with [111In-DTPA0]octreotide in patients (369 citations)
- Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience (339 citations)
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors (333 citations)
What are the main themes of her work throughout her whole career to date?
Marion de Jong mainly investigates Radionuclide therapy, Internal medicine, Endocrinology, Somatostatin and Biodistribution.
Her research integrates issues of Neuroendocrine tumors, Cancer research, Octreotate and Pharmacology in her study of Radionuclide therapy.
The Internal medicine study combines topics in areas such as Oncology and DOTA.
Her Endocrinology study combines topics in areas such as Internalization, Toxicity and Peptide.
Her study in Somatostatin receptor and Octreotide falls within the category of Somatostatin.
Marion de Jong studied Somatostatin receptor and Pathology that intersect with Ex vivo.
She most often published in these fields:
- Radionuclide therapy (39.38%)
- Internal medicine (36.30%)
- Endocrinology (31.16%)
What were the highlights of her more recent work (between 2015-2021)?
- Radionuclide therapy (39.38%)
- Cancer research (19.86%)
- Biodistribution (20.55%)
In recent papers she was focusing on the following fields of study:
The scientist’s investigation covers issues in Radionuclide therapy, Cancer research, Biodistribution, Pharmacology and Receptor.
Her research in Radionuclide therapy intersects with topics in Absorbed dose, Dosimetry, Octreotate, Radiochemistry and Neuroendocrine tumors.
Her studies deal with areas such as Ex vivo and Somatostatin as well as Neuroendocrine tumors.
Her Cancer research research includes elements of Cancer, Prostate cancer, Somatostatin receptor and Radionuclide imaging.
Her Biodistribution research incorporates elements of Pharmacokinetics and Nuclear medicine.
Her Receptor research is within the category of Internal medicine.
Between 2015 and 2021, her most popular works were:
- Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results (67 citations)
- Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models (56 citations)
- Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT (54 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Biochemistry
Marion de Jong mainly investigates Radionuclide therapy, Cancer research, Biodistribution, Prostate cancer and Antagonist.
Her Radionuclide therapy study is focused on Internal medicine in general.
The study incorporates disciplines such as Breast cancer, Somatostatin receptor, Endocrinology and Pathology in addition to Cancer research.
She combines subjects such as Agonist and Estrogen receptor with her study of Somatostatin receptor.
Her Biodistribution research is multidisciplinary, incorporating elements of Combinatorial chemistry, Chemical modification and Pharmacology.
As part of the same scientific family, she usually focuses on Antagonist, concentrating on Cancer and intersecting with Pancreas.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
